Plain-English translation of NCT05040217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing AAV2-BDNF, a new gene therapy approach for people with early Alzheimer's disease or mild cognitive impairment. The treatment works by delivering a natural brain growth factor directly into key memory centers of the brain to help protect nerve cells, reduce cell loss, and strengthen connections between brain cells. Because this medication cannot cross the protective barrier that surrounds the brain, gene therapy is used to deliver it directly to where it's needed.
Currently, there are limited treatment options that can slow or stop memory loss in early Alzheimer's disease. This trial exists to test whether this medication can help protect brain cells and improve thinking and memory, based on promising results from similar gene therapy studies in other brain disorders.
You would undergo a one-time surgical procedure to receive the gene therapy treatment delivered directly to specific memory centers in your brain. After the procedure, you would attend follow-up clinic visits so the research team can monitor your safety and test whether the treatment is helping your memory and thinking. Your caregiver would be an important part of your participation, attending visits with you and watching for any side effects throughout the study.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States